勃起功能障碍基因疗法的现状
摘要： Current available treatment options for erectile dysfunction (ED) are effective but not without failure and/or side effects. Although the development of phosphodiesterase type 5 (PDE5) inhibitors (I.e. Sildenafil, tadalafil and vardenafil) has revolutionized the treatment of ED, these oral medications require on-demand access and are not as effective in treating ED related to diabetic, post-prostatectomy and severe veno-occlusive disease states. Improvement in the treatment of ED is dependent on understanding the regulation of human corporal smooth muscle tone and on the identification of relevant molecular targets. Future ED therapies might consider the application of molecular technologies such as gene therapy. As a potential therapeutic tool, gene therapy might provide an effective and specific means for altering intracavernous pressure "on demand" without affecting resting penile function. However, the safety of gene therapy remains a major hurdle to overcome before being accepted as a mainstream treatment for ED. Gene therapy aims to cure the underlying conditions in ED, including fibrosis. Furthermore, gene therapy might help prolong the efficacy of the PDE5 inhibitors by improving penile nitric oxide bioactivity. It is feasible to apply gene therapy to the penis because of its location and accessibility, low penile circulatory flow in the flaccid state and the presence of endothelial lined (lacunar) spaces. This review provides a brief insight of the current role of gene therapy in the management of ED.
-
生活方式对亚洲男性性激素、性活动以及老龄化的调节作用
-
70W和120W2微米激光汽化切除良性前列腺增生的体外对比研究
-
中国人类精子库捐精现状及应用:7年多中心回顾性研究
-
西地那非联合多沙唑嗪缓释剂治疗勃起功能障碍合并良性前列腺增生相关下尿路症状患者疗效的开放对照多中心临床评估
-
体重指数及血脂水平与血清前列腺特异抗原的关系:一组中国50岁以下人群的研究
-
血清PSA水平与非癌变前列腺组织体积的比值是接受前列腺癌根治术患者局部晚期前列腺癌生化复发的新指标
-
人精子纤维鞘内CABYR蛋白与AKAP3及Ropporin蛋白结合
-
芳香化酶(CYP19)基因变体同精子浓度和活性的关系
-
治疗前列腺癌的化疗新策略:一种新的Eg5抑制剂S-(methoxytrityl)-L-cysteine
-
ERβ基因RsaI多态性可能降低精子受精力及胚胎的发育潜能
